Pliant Rx (PLRX) Enterprise Value to EBITDA Ratio

Public company logo of Pliant Therapeutics, Inc. (PLRX)

The EV/EBITDA multiple for Pliant Therapeutics (PLRX), which stands at 0.00, confirms a reduction in portfolio risks driven by positive test results and support from US regulators. The business relies on non-cyclical anti-fibrosis developments with long-term planning and no seasonality. Pliant Therapeutics (PLRX) is creating a unique integrin blocking system to combat organ scarring, offering an innovative method for patient rescue.

Pliant Therapeutics, Inc. - PLRX Company Value to EBITDA (period 11/23/2025 - 11/12/2026)

Comprehensive metric breakdowns and analytics for pliantrx.com (PLRX)

- current price and projected stock value:
Stock Price Pliant Therapeutics, Inc.|PLRX - Analyst Median Target
- market capitalization details:
Market Valuation PLRX|PLRX - Full Business Value
- business book valuation details:
Book Value per Share Pliant Therapeutics|PLRX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio pliantrx.com|PLRX - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Pliant Therapeutics|PLRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Pliant Therapeutics, Inc.|PLRX - Company Aggregate Indebtedness|Debts to Book Capitalization PLRX|PLRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Pliant Therapeutics|Quick Liquidity pliantrx.com
- financial results and valuation multiples details:
PLRX - Final Profit|Expected Profit Pliant Therapeutics|PLRX - Price to Earnings Ratio|Forward P/E Multiple Pliant Therapeutics, Inc.|PLRX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PLRX|PLRX - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Pliant Therapeutics|PLRX - Earnings per share for the last twelve months|Quarterly EPS earnings growth pliantrx.com|PLRX - Expected net earnings per share growth this year|Earnings growth forecast for next year Pliant Therapeutics
Fundamental valuation:Pliant Rx PLRX
Manufactured products of Pliant Therapeutics, Inc.

For Pliant Therapeutics (PLRX), the link between operational efficiency and market value is critical, as this metric compares the total asset price, including debt, to EBITDA. Analyzing the EV/EBITDA multiple on a time chart allows for an assessment of the investment attractiveness of Pliant Therapeutics (PLRX), whose expertise in fibrosis therapy and successful clinical trials create a foundation for strategic deals and business revaluation.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PLRZ|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTH (Cyclo Therapeutics, Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|INZY (Inozyme Pharma Inc.) - EV/EBITDA Multiple|reneopharma.com (RPHM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CSCI